MyDosageBeta
Goals/04
Guided intelligence brief

Longevity & markers.

Longevity is the hardest category to grade: endpoints are decades-long. We surface mechanistic and biomarker evidence and label the rest honestly.

01Mechanisms

How this class moves the outcome.

01

Telomere / chromatin signalling

Epitalon is studied for telomerase modulation in cell culture; translation to organism-level lifespan in humans is unestablished.

02

Immune system maintenance

Thymic peptides (thymosin-α1, thymulin) modulate T-cell function — relevant to immunosenescence with age.

03

Connective-tissue / skin signalling

GHK-Cu drives collagen and elastin gene expression — the most-studied 'visible aging' mechanism in this set.

02Candidate compounds

Ranked by human-evidence strength.

  1. 01

    Epitalon

    Epithalon

    Russian synthetic pineal-gland tetrapeptide. Marketed for longevity; evidence largely Russian/in-house.

    Pineal tetrapeptidet½ ShortPreclinical only
    CPreclinical only
    3.9EIS™ · Emerging
    Open full brief →
  2. 02

    GHK-Cu

    Copper Tripeptide-1

    Naturally occurring copper-binding tripeptide. Topical use studied for skin remodelling; injectable use is anecdotal.

    Copper-binding tripeptidet½ Short (minutes, plasma)Human observational
    BHuman observational
    5.2EIS™ · Emerging
    Open full brief →
  3. 03

    Thymulin

    FTS

    Zinc-bound thymic peptide with immunomodulatory and analgesic properties in animal models.

    Zinc-dependent thymic peptidet½ ShortPreclinical only
    CPreclinical only
    3.7EIS™ · Emerging
    Open full brief →
  4. 04

    Thymosin α1

    Zadaxin

    Thymic-origin peptide marketed as Zadaxin in 30+ countries (not US) for chronic hepatitis B/C and as adjuvant.

    Thymic peptide (28-aa)t½ ~2 hHuman RCT
    AHuman RCT evidence
    6.4EIS™ · Moderate
    Open full brief →
03Human evidence

What the human data actually shows.

Brief composition
Evidence composition4 entries
RCT 1 Obs 1 Pre 2

Each bar is the proportion of candidates on this brief at that evidence tier. RCT first, observational second, preclinical and anecdotal labeled and never inflated.

See full methodology →
Outcome matrix
Skin appearance / collagen markers
Topical GHK-Cu has the strongest dermatology data.
Bgrade
6.6
Immune marker normalisation (elderly)
Older Russian/Eastern-European literature, small N.
Cgrade
5.2
Biological-age biomarker change
Reported, not reliably replicated.
Dgrade
3.0
All-cause mortality reduction
No human RCT reads on this endpoint.
Dgrade
1.8
Top studies behind this brief

Indexed human trials and reviews driving the candidate rankings above. Sorted by study type, then recency.

3 shown
04Risks & limitations

Where this class can hurt you.

Top class-level risks
  • Most clinical literature is small-N, single-group, and decades old.
  • Biomarker improvement does not guarantee clinical longevity benefit.
  • Long-term combination use with other immunomodulators is under-studied.
What we still don't know
  • No human trial reads out on hard mortality endpoints for any of these.
  • Biomarker improvement does not guarantee clinical longevity benefit.
05Comparison

Decide between candidates.

Put the top 4 candidates side by side.

Mechanism · half-life · routes · evidence tier · safety signals. A decision matrix, not a leaderboard.

Open the matrix →Ask the assistant
06Consensus engine

Current scientific consensus.

3.8/ 10
Overall confidence
Emerging
Human evidence
Emerging
Risk profile
Low-Moderate
Strongest supported
  • Topical skin / collagen outcomes (GHK-Cu)
Weak / unclear claims
  • Direct lifespan extension
  • Biological-age reversal
Major unknowns
  • Whether biomarker change translates to clinical longevity
  • Optimal cycling / duration
Editorial outlook

"An honest 'too early' category. The most credible wins are cosmetic and immune-marker. Lifespan claims are not supported."

07Long-term outlook

Where this is heading.

An honest 'too early' category. The most credible wins are cosmetic and immune-marker. Lifespan claims are not supported.

We re-grade this brief quarterly. Confidence and outcome grades shift as new RCTs publish, safety data accumulates, and replication efforts read out. Changes are logged publicly on the evidence changelog.

Methodology →Changelog →Safety surface →
06Canonical, evidence-anchored

Matched protocol templates.

Matching templates…